描述
Rilertinib Mesylate Product Specifications
Attribute | Details |
---|---|
Product Name | Rilertinib Mesylate Tablets (Sanrisso®) |
Dosage | 100?mg per tablet × 20 tablets per bottle |
Formulation | Oral film-coated tablet |
Approval No. | China NMPA H20240020 |
Drug Code | 86901583000930 |
Manufacturer | Nanjing Sanhome Pharmaceutical Co., Ltd. |
Intended Use | Laboratory research only—Not for human or veterinary use |
? Overview & Mechanism
Rilertinib mesylate (Sanrisso®) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets activating mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It exhibits potent anti-tumor activity against EGFR-mutant NSCLC cell lines and tumor models.
? Research & Clinical Context
-
China NMPA Approval (Feb 2025): Approved for patients with EGFR T790M mutation-positive advanced or metastatic NSCLC after progression on prior EGFR-TKI therapy.
-
Phase III Trials: Demonstrated superior progression-free survival (PFS) compared to gefitinib in EGFR-mutant NSCLC patients.
? Research Applications
Ideal for:
-
EGFR pathway and T790M-resistance mechanisms
-
In vitro and in vivo NSCLC models
-
Drug resistance and combination therapy studies
-
Pharmacokinetic and pharmacodynamic profiling
? Handling & Storage
-
Storage: Store at 20–25?°C, sealed and protected from light and moisture.
-
Handling: Use appropriate laboratory personal protective equipment (PPE); avoid ingestion or inhalation.
? References
-
NMPA approval announcement (Feb 19, 2025)
-
Phase III trial results comparing rilertinib vs gefitinib
-
Drug mechanism and development synopsis
tinknocke –
The logistics was very fast, I received it in 8 days